Cipla’s manufacturing facility at Pithampur, Indore receives “Official Action Indicated” classification from U.S. FDA for not meeting regulatory requirements; OAI status may delay/hold product pending approval

Pharmaceutical tablets and capsules are arranged on table in photo illustration

BENGALURU, Aug 5 (MeelBijendra) – Late on Saturday night, Indian drugmaker Cipla received an ‘Official Action Indicated’ (OAI) classification from the United States Food and Drug Administration’s (USFDA) inspection carried out in February 2023 at Cipla’s manufacturing facility in Pithampur, Indore. The United States Food and Drug Administration (USFDA), an agency of the United States … Read more

Cipla signs binding term sheet to sell its entire stake in Saba Investments; Deal worth US$6.50 million

Indian rupee notes

Indian multinational pharmaceutical company Cipla Limited announced the sale of its entire stake in Saba Investments Limited on 15 May 2023. Saba Investments Limited is a UAE-based Joint Venture between Cipla Limited and Shibam Group Holding Limited. Read Also: Tech Mahindra Ltd approves proposal to increase stake in Tech Mahindra Arabia Ltd to 80% by … Read more